Ventaris Surgical, a San Carlos, California-based medical device company, has closed a $30 million Series A financing round to advance a ureteroscopic platform designed to improve stone clearance during kidney stone procedures. The round was led by Longitude Capital, with new investor Vensana Capital also participating. Existing backers Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners also joined the financing.
As part of the deal, Varun Gupta of Longitude Capital and Justin Klein of Vensana Capital will join Ventaris’ board of directors, alongside independent board member Amir Abolfathi, the company said.
Ventaris is developing a ureteroscopic system designed to help surgeons achieve more consistent and complete stone clearance. The company noted that kidney stone surgery is among the most common urologic interventions, but outcomes can vary due to factors such as patient anatomy, stone burden, workflow constraints, and surgeon fatigue.
Ventaris said the funding will be used to support ongoing clinical development and to advance regulatory and commercial milestones.
KEY QUOTES:
“Ventaris’ technology has the potential to both improve outcomes and reduce the burden on surgeons. Their approach resolves several critical unmet needs in today’s standard of care.”
Maxwell Bikoff, Managing Director, Longitude Capital
“Kidney stone surgery demands an exceptional level of skill, focus, and persistence. Surgeons are often willing to invest the time and effort required to pursue complete stone clearance, but today’s tools can make that goal difficult to achieve consistently. Ventaris was founded with the goal of removing unnecessary friction from the procedure, so that surgeons can focus their time and effort on reliably achieving complete stone clearance. We are excited to embark on this next phase of growth with Longitude Capital and Vensana Capital.”
Surag Mantri, CEO, Ventaris Surgical
